The history of biomarkers in psychiatry: lessons learned, lessons forgotten, lessons rediscovered.

A quirky truth is that the oldest biomarker findings are largely metabolic. These had minimal impact on contemporary thought and research and were largely ignored. They have been rediscovered and validated almost 100 years later, informing our understanding of neurobiology and medical comorbidity and spurring contemporary treatment discovery efforts.

Immuno-metabolic depression: from concept to implementation.

Major depressive disorder is a common, disabling mental disorder characterized by extensive etiological and phenotypic heterogeneity. This heterogeneity makes treatment approaches imprecise and often ineffective. Insight into the underlying biological mechanisms underpinning depression and its subtypes may enable more personalized treatments.

Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review.

Mitochondria are organelles involved in different cellular functions, especially energy production. A relationship between mitochondrial dysfunction and mood disorders, especially bipolar disorder (BD), has been reported in the scientific literature, which suggests altered energy production and higher levels of oxidative stress compared to healthy controls. Specifically, in BD, the hypothesis of a biphasic pattern of energy availability has been postulated according to mood states.

Effect of ketamine on anxiety: findings from the Ketamine for Adult Depression Study.

Background: Anxiety disorders and treatment-resistant major depressive disorder (TRD) are often comorbid. Studies suggest ketamine has anxiolytic and antidepressant properties.

Aims: To investigate if subcutaneous racemic ketamine, delivered twice weekly for 4 weeks, reduces anxiety in people with TRD.